PMEF
STOK icon

Point72 Middle East FZE’s Stoke Therapeutics STOK Stock Holding History

Point72 Middle East FZE’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,721
Closed -$15.9K – 2181
2022
Q4 		$15.9K Buy
+1,721
New +$17.9K ﹤0.01% 1678

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Middle East FZE's STOK Position: Q1 2023 in Review

Point72 Middle East FZE sold out of Stoke Therapeutics (STOK) in Q1 2023, closing a stake of 1,721 shares — an estimated $15.9K sold.

Point72 Middle East FZE first reported a position in STOK in Q4 2022 and held it in 1 quarter. The position peaked at $15.9K in Q4 2022. 96 funds tracked by Wall St. Rank hold STOK as of Q1 2023.

  • Point72 Middle East FZE reported no remaining Stoke Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,721 Stoke Therapeutics shares in Q1 2023, an estimated $15.9K.
  • Point72 Middle East FZE first reported a position in Stoke Therapeutics in Q4 2022 and held it in 1 quarter.
  • Point72 Middle East FZE's Stoke Therapeutics position peaked at $15.9K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.